Minakem Header W48

Minakem Header W48

X

[{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Pharmaceutical Services Selected by Lundbeck To Provide VYEPTI\u2122 (eptinezumab-jjmr) ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AHS Posters for Lundbeck\u2019s VYEPTI in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Journal of the AMA Publishes Data on Efficacy of VYEPTI","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck to Showcase New VYEPTI\u00ae (eptinezumab-jjmr) Data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck Reports Positive Results For Vyepti[\u00ae] (Eptinezumab) From the DELIVER Study in Patients with Migraine and Prior Preventive Treatment Failures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck to Present Data on VYEPTI\u00ae (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"H. Lundbeck AS"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

H. Lundbeck AS

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lundbeck to Present Data on VYEPTI® (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence ...

Details:

The safety of Eptinezumab-jjmr was evaluated in 2,076 patients with migraine who received at least one dose of VYEPTI. The most common adverse reactions in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

Lead Product(s): Eptinezumab

Therapeutic Area: Neurology Product Name: Vyepti

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2022

ASK
US

Upload
your Pipeline Activity

H. Lundbeck AS

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

Details:

Poster presentation of exploratory analysis from PROMISE 2 showed VYEPTI was associated with greater declines in headache frequency and days of acute headache medication use vs. placebo in people dually diagnosed with chronic migraine and medication overuse headache.

Lead Product(s): Eptinezumab

Therapeutic Area: Neurology Product Name: Vyepti

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 02, 2022

ASK
US

Upload
your Pipeline Activity

H. Lundbeck AS

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lundbeck Reports Positive Results For Vyepti[®] (Eptinezumab) From the DELIVER Study in Patients with Migraine and Prior Preventive Treatment Failures

Details:

Vyepti is a humanized monoclonal antibody that binds to CGRP which was purposefully developed for IV administration met its primary endpoint of decrease in MMDs over weeks 1-12 in both episodic and chronic migraine.

Lead Product(s): Eptinezumab

Therapeutic Area: Neurology Product Name: Vyepti

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 01, 2021

ASK
US

Upload
your Pipeline Activity

H. Lundbeck AS

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

The Journal of the AMA Publishes Data on Efficacy of VYEPTI

Details:

Patients receiving VYEPTI reported a median time to headache pain freedom of 4 hours vs. 9 hours among those who received placebo, and a median time of 2 hours to the absence of their MBS vs. 3 hours with placebo.

Lead Product(s): Eptinezumab

Therapeutic Area: Neurology Product Name: Vyepti

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2021

ASK
US

Upload
your Pipeline Activity

H. Lundbeck AS

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lundbeck to Showcase New VYEPTI® (eptinezumab-jjmr) Data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)

Details:

VYEPTI met its primary endpoint of decrease in mean monthly migraine days (MMD) over months 1-3 in both episodic and chronic migraine. The safety of VYEPTI was evaluated in 2,076 patients with migraine who received at least one dose of VYEPTI.

Lead Product(s): Eptinezumab

Therapeutic Area: Neurology Product Name: Vyepti

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2021

ASK
US

Upload
your Pipeline Activity

H. Lundbeck AS

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AHS Posters for Lundbeck’s VYEPTI in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache

Details:

Post-hoc closed testing analysis suggests onset of a migraine preventive effect with intravenous VYEPTI as early as day 1 following the initial dose.

Lead Product(s): Eptinezumab

Therapeutic Area: Neurology Product Name: Vyepti

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 13, 2020

ASK
US

Upload
your Pipeline Activity

H. Lundbeck AS

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Orsini Pharmaceutical Services Selected by Lundbeck To Provide VYEPTI™ (eptinezumab-jjmr)

Details:

Orsini Pharmaceutical has been selected as one of a very limited number of distribution partners for VYEPTI™ (eptinezumab-jjmr).

Lead Product(s): Eptinezumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Orsini Specialty Pharmacy

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 22, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY